Computer-aided digital chest radiograph interpretation (CAD) can facilitate high-throughput screening for tuberculosis (TB), but its use in population-based active case-finding programs has been limited. In an HIV-endemic area in rural South Africa, we used a CAD algorithm (CAD4TBv5) to interpret digital chest x-rays (CXR) as part of a mobile health screening effort. Participants with TB symptoms or CAD4TBv5 score above the triaging threshold were referred for microbiological sputum assessment. During an initial pilot phase, a low CAD4TBv5 triaging threshold of 25 was selected to maximize TB case finding. We report the performance of CAD4TBv5 in screening 9,914 participants, 99 (1.0%) of whom were found to have microbiologically proven TB. CAD4TBv5 was able to identify TB cases at the same sensitivity but lower specificity as a blinded radiologist, whereas the next generation of the algorithm (CAD4TBv6) achieved comparable sensitivity and specificity to the radiologist. The CXRs of people with microbiologically confirmed TB spanned a range of lung field abnormality, including 19 (19.2%) cases deemed normal by the radiologist. HIV serostatus did not impact CAD4TB’s performance. Notably, 78.8% of the TB cases identified during this population-based survey were asymptomatic and therefore triaged for sputum collection on the basis of CAD4TBv5 score alone. While CAD4TBv6 has the potential to replace radiologists for triaging CXRs in TB prevalence surveys, population-specific piloting is necessary to set the appropriate triaging thresholds. Further work on image analysis strategies is needed to identify radiologically subtle active TB.

INTRODUCTION

Tuberculosis (TB) continues to cause over 1 million deaths annually, challenging the WHO strategy to reduce deaths due to TB by 95% by 2035. Efficient strategies to find the “missing millions” are of particularly high priority in resource-limited settings where TB burden is high and access to diagnostics may be limited. In this context, community-based screening programs may play an important role in increasing case finding. However, these programs are challenged by the high costs of TB diagnostic tests, including molecular tests such as Xpert MTB/RIF and microbiological culture. The WHO recommends using chest radiography to select individuals with lung field abnormalities for sputum testing. However, this approach requires a workforce of radiologically trained clinicians to interpret chest x-rays (CXR), which is often limited in rural low-resource settings.

Computer-aided detection (CAD) systems have the potential to make TB screening programs more efficient by rapidly detecting TB-related abnormalities in digital CXRs. In December 2020, the WHO announced that forthcoming recommendations for systematic screening for TB will include the deployment of CAD algorithms. One commercial product, CAD4TB (“Thirona, Nijmegen, the Netherlands”) scores CXRs on a scale from 0 to 100 according to the degree of abnormality and the likelihood of TB. Previous studies have shown that CAD4TB can identify CXRs with abnormal lung fields and TB-related features, such as cavities and consolidation, and reduce the cost for microbiologic diagnostics. Using CAD for triage requires selecting a decision threshold score above which participants are referred for sputum testing. Although a universally applicable threshold would be useful, several studies have suggested that threshold selection should be adjusted according to the factors unique to each setting, including the underlying TB prevalence, demographic parameters, type, and number of available microbiological tests. Another consideration that may impact computer-assisted CXR interpretation is that HIV-positive patients may show atypical radiological signs of TB. So far, CAD4TB has been mainly evaluated in clinical settings in which symptomatic patients seek diagnostic evaluation. One study evaluated CAD4TB version 5 (CAD4TBv5) retrospectively at a diabetes-care center in Indonesia and found that triaging threshold 65 had 88.9% sensitivity. Performance reports from population-based screening programs of asymptomatic individuals are limited. One study applied CAD4TBv5 retrospectively in a population-based setting and suggested lowering the CAD4TB score threshold for triaging compared with a clinical setting. How best to determine thresholds in prospective applications for active case-finding remains an unanswered question.
Here we report the prospective application of CAD4TBv5 as a triaging tool during a community-based multi-morbidity survey in a TB- and HIV-endemic area in rural South Africa. Mobile health camps were used to provide free health assessment to local residents over the age of 15 years, including measurement of body mass index (BMI), blood pressure and glycosylated hemoglobin (HbA1c), and HIV status. The goal of the TB component of the survey was to identify as many active TB cases as possible and to describe the full spectrum of TB disease in the population (Supplementary Fig. 1). Following WHO guidelines, we aimed to triage participants for sputum testing if they reported TB-related symptoms or if they had abnormal lung fields on CXR.

Because it was infeasible to employ a radiologist to review CXRs in real-time in the mobile health camp, we applied CAD4TBv5 to indicate lung field abnormality as triaging criterion for sputum collection. Sputum was subjected to Xpert Ultra MTB/RIF (Xpert Ultra) and liquid mycobacterial culture. A senior radiologist, who was blinded to CAD4TB output and other participant data, interpreted each CXR in a central reading setting and assessed whether a) lung fields were normal or abnormal, and b) if abnormal, whether the findings were diagnostic of active TB.

Participants who were determined to have abnormal lung fields by the radiologist but whose CAD4TB scores were below the triaging threshold were visited at home by the research team to collect a sputum sample for microbiological assessment. Here we report the process by which we selected a triaging threshold to maximize the number of participants with abnormal lung fields that were triaged for sputum collection at the mobile health camp and the performance of CAD4TBv5 (and its successor CAD4TBv6) to identify active TB on CXRs obtained in a community-based prevalence survey.

RESULTS

Selection of a CAD4TBv5 triaging threshold

During a pre-planned pilot phase of the survey, 1090 participants underwent chest radiography and were triaged for sputum examination based on a CAD4TBv5 triage threshold of 60, a threshold that had been chosen to be more than 80% sensitive for active TB based on existing literature at the time. At this threshold, CAD4TBv5 identified only 54 of 198 (27.3%) CXRs which the radiologist subsequently determined to have abnormal lung fields. Participants were considered incorrectly triaged if they were ultimately found to have lung field abnormality by the radiologist, but had been sent home without sputum collected at the mobile health camp. In total, 109 (83.2%) of the incorrectly triaged participants (n = 131) eventually had successful sputum collection at home, and 22 (16.8%) of incorrectly triaged participants could not be contacted for a follow-up visit and therefore did not have sputum collected. The high rate of incorrect triaging posed logistical challenges to the operation of the survey. Using the radiologist’s assessment of lung field abnormality as a gold standard, the range of CAD4TBv5 scores was between 10 and 100 for normal (median 23, interquartile range (IQR) 20–28) and overlapped with those for abnormal lung fields (range 17–100, median 43, IQR 30–61) (Supplementary Fig. 2). In order to minimize the number of participants that were incorrectly triaged in the field and maximize TB case-finding, a triaging threshold of 25 was determined to be optimal for the main phase of the study. At this threshold, the sensitivity for detecting lung field abnormality was as high as possible (84.8%) (95% confidence interval (CI): 79.1–89.5) given the trade-off in specificity (65.7; CI: 62.5–68.8, Supplementary Fig. 3), which had to account for the increased burden on the laboratory to perform sputum molecular and microbiological testing.

Characteristics of participants with TB

A total of 10,320 participants were enrolled in the screening program (Fig. 1). In total, 406 participants could not have chest radiography due to pregnancy or physical inability to climb into the mobile van; they are excluded from this analysis of CAD4TB performance. Based on their CXR findings and microbiology results, 9914 participants were categorized as having (1) “definite TB”, defined by microbiological evidence of Mycobacterium tuberculosis (Mtbc) in the sputum (either positive MTB/RIF XpertUltra or Mtbc culture); (2) “probable TB”, defined as radiological findings consistent with active TB without any microbiological evidence of TB; or (3) “no evidence of active TB”, defined by the absence of radiological and microbiological evidence of TB. The median age of participants in the survey was 39 years (interquartile range (IQR) 24–59), 29.8% (2954 of 9914) were HIV-positive, and 10.7% (1056 of 9914) presented with at least one TB-related symptom. Among the 99 participants (1.0%) who met the definition for definite TB, only 20 (20.2%) reported any TB symptom (Table 1). According to the radiologist’s assessment of the CXRs from this group, 30 (30.3%) had lung field abnormalities diagnostic of TB and 80 (80.8%) had any lung field abnormality. The median CAD4TBv5 score of this group was 63 (IQR 44–77.5, range 19–100). The wide spectrum of lung field abnormality and CAD4TBv5 scores observed among participants with definite TB is illustrated by two examples from the extremes of the spectrum: the first with prominent radiological abnormalities deemed by the radiologist to be consistent with active TB and by CAD4TBv5 as highly consistent with TB with a score of 95 (Fig. 2a–b), and the second with lung fields deemed normal by the radiologist and by CAD4TBv5 as having a low likelihood of active TB with a score of 39 (Fig. 2c–d). Notably, both these participants reported being asymptomatic and were therefore triaged for sputum collection based on their CAD4TBv5 scores alone.

Among the participants with definite TB, 24 had an XpertUltra “trace” result (lowest level in the semiquantitative scale) as the only microbiological evidence of TB. These participants were excluded from the more stringent subgroup, “definite TB, trace only excluded” (75/9,914, 0.76%, Fig. 1), which was defined to allow sensitivity analyses due to emerging uncertainty about the clinical significance of the XpertUltra “trace” laboratory result when present in isolation. The median CAD4TBv5 score for this group was 66 (IQR 51.5–84) and did not differ significantly from the definite TB group (median 63 (IQR 43–78), p-value = 0.43). An additional 172 (1.7%) participants met the definition of “probable TB” and the median CAD4TBv5 score in this group was significantly higher (87 (IQR 73–95), p-value = 5.3 x 10^-11) than in the definite TB group. In individuals with definite and probable TB, there were no significant differences for either version of CAD4TB when groups were stratified by HIV status (p-values > 0.05, Fig. 3).

Performance of CAD4TB as a tool to triage participants for sputum examination

We assessed the performance of CAD4TBv5 and v6 to correctly triage participants with definite TB compared with the expert radiologist’s performance (Supplementary Tables 1, 2, and 3). The radiologist’s triage sensitivity for definite TB (80.8%, CI: 71.7–88.0), was most closely comparable to CAD4TBv5’s performance between the scores of 39 and 40 (39: 82.8% (CI: 73.9–89.7), 40: 79.8% (CI: 70.5–87.2), and CAD4TBv6’s performance between the scores of 47 and 48 (47: 82.8% (CI:73.9–89.7), 48: 76.8% (CI: 67.2–84.7), Table 1). At these thresholds, the specificity of CAD4TBv5 (39: 55.4 (CI: 54.0–56.8), 40: 57.4% (CI: 56.0–58.8)) was lower than that of the radiologist (66.9 (CI: 65.6–68.2)). The specificity of CAD4TBv6 at these thresholds was higher (47: 62.6 (CI: 61.2–64), 48: 68.0 (CI: 66.7–69.3)) and in the same range as the radiologist. At these thresholds, CAD4TBv5 also had lower (39: 3.6% (CI: 2.9–4.5), 40: 3.7% (CI: 2.9–4.5)) and CAD4TBv6 had similar...
Fig. 1  TB screening in the first year of Vukuzazi. A total of 10,320 participants were enrolled, of which 9914 underwent chest radiography. Participants were triaged for sputum collection if they had symptoms or if their CAD4TBv5 score was equal to or above the triaging threshold. For triaged participants who could spontaneously produce a sputum sample \( (n = 4976) \), the sputum was tested with Xpert MTB/RIF Ultra and liquid culture. Independently, the radiologist indicated whether chest radiographs were normal or abnormal and if abnormal were diagnostic of active TB. If the radiologist indicated abnormal lung fields among participants who were not triaged in the camp, the sputum was collected during a home visit. Participants were grouped into definite (microbiologically confirmed), probable (radiologically diagnosed), and no evidence of TB. A more stringent subgroup of definite TB excluded participants whose only microbiological evidence of TB was an Xpert Ultra “trace” result.

precision (positive predictive value) (47: 4.3% (CI: 3.4–5.3), 48: 4.6% (CI: 3.7–5.8)) when compared with the radiologist (4.7% (CI: 3.8–5.8)).

CAD4TB’s triage performance to detect the more stringent subgroup (definite TB, trace excluded) did not differ significantly from its performance to detect definite TB \( (v5: \text{AUC} 0.82 (0.77–0.87) \text{ vs. AUC} 0.78 (0.73–0.83); v6: 0.84 (0.79–0.89) \text{ vs. 0.79 (0.73–0.84)}, p=0.28, \text{Fig. 4a–b, Supplementary Table 4}).

However, CAD4TB’s triage performance for the detection of probable TB (for both v5 and v6: AUC 0.96, CI: 0.95–0.98) was superior to its performance for the detection of definite TB \( (v5: \text{AUC} 0.78 (0.73–0.83), v6: \text{AUC} 0.79 (0.73–0.84), p<0.001 \text{in Supplementary Table 5, Fig. 4a–b}). The performance of CAD4TB did not differ significantly when participants were stratified by HIV status (Supplementary Table 6). Similarly, the area under the precision-recall curve (PRAUC) was lowest for definite TB trace excluded (both v5 and v6: 0.08) and definite TB (both v5 and v6: 0.09) and highest for probable TB (v5: 0.42, v6: 0.44) (v5: Supplementary Fig. 4a and v6: Supplementary Fig. 4b).

If the radiologist’s definition of abnormal lung fields had been used for field triage, 20.2% (2,002) of participants would have required sputum testing, (Table 2, Fig. 4c). At triaging thresholds that matched the radiologist’s sensitivity, CAD4TBv5’s would have required testing a larger percentage of participants (39: 28.4% (2,820), 40: 27.0% (2,677)) and CAD4TBv6 would have required testing a percentage of participants similar to the radiologist (47: 23.7% (2,348), 48: 20.1% (1,997), Table 2 and Fig. 4c). The radiologist’s number needed to test to identify one person with definite TB (NNT) was 25, which was lower compared with CAD4TBv5 (39: 34, 40: 34) and similar to CAD4TBv6 (47: 29, 48: 26,
**DISCUSSION**

We used CAD4TBv5 to interpret digital CXRs in a community-based multi-disease screening survey in rural South Africa and found that CAD4TB could perform similarly to an expert radiologist in triaging participants for diagnostic sputum testing. At a triaging threshold 39, CAD4TBv5 had a similar sensitivity but slightly lower specificity than the radiologist; however, retrospective analysis of the next generation of the algorithm, CAD4TBv6, showed that a triaging threshold of 47 had equivalent sensitivity and improved specificity, making its performance comparable to that of the radiologist. At a triaging threshold of 47, CAD4TBv6 would have triaged slightly more participants (346) for sputum testing and identified 2 more TB cases than the radiologist.

The importance of screening for TB in community-based non-clinical settings is increasingly recognized. Our study, which used mobile health camps in a rural area, found that 1.0% of the screened population had microbiologically proven TB cases, and that 79.8% of these individuals were asymptomatic. This finding is in line with a recent study from a population-based screening in urban Uganda, which showed that individuals newly diagnosed with active TB in community-based screening have fewer symptoms, compared with people diagnosed at health facilities. It is also in line with the recently completed South African National TB prevalence survey (57.7% asymptomatic) and a recent meta-analysis of global TB prevalence surveys (79–97% asymptomatic). Asymptomatic TB eludes traditional symptom-based TB screening algorithms but is identifiable by CXR abnormality in most cases. Because of this, the WHO has recently announced that upcoming TB screening guidelines will recommend a symptom-agnostic community-based approach using CXR surveys. Our results suggest that using CAD4TBv6 to triage digital CXRs will increase the yield of active case-finding programs compared with symptom-based triage and is feasible in rural low-resource settings. The truck containing the radiography unit for our study was equipped with solar panels that powered the x-ray equipment and computer, allowing it to be used without external sources of electricity. The off-line CAD4TB algorithm interpreted CXRs for triaging within one minute of their capture without requiring an active internet connection. The numerical CAD4TB read-out made it straightforward for non-clinical staff to appropriately direct participants for sputum collection. Portable digital radiography units and CAD algorithms that perform comparably to an expert radiologist make large-scale CXR screening feasible and relevant to find the missing millions of undiagnosed TB.

In addition to often being asymptomatic, TB detected through community-based screening may have its own spectrum of radiological features compared with TB diagnosed in clinics and hospitals, making it a distinct use-case for automated imaging algorithms. To date, CAD4TB has most frequently been used in healthcare centers to triage symptomatic patients with limited published data on its performance in symptom-agnostic screening programs. In this study, our decision to use an intentionally low CAD4TBv5 triaging threshold referred the

### Table 1. Demographics, clinical and radiological characteristics of study participants.

| Characteristic                                      | Enrolled individuals with CXR | Definite TB | Definite TB trace excluded | Probable TB | No TB |
|-----------------------------------------------------|------------------------------|------------|----------------------------|------------|------|
| N                                                   | 9914 (100)                   | 99 (1.0%)  | 75 (0.8%)                  | 172 (1.7)  | 9643 (97.3) |
| Female                                              | 6664 (67.2)                  | 49 (49.5)  | 35 (46.7)                  | 76 (44.2)  | 6539 (67.8) |
| Age*                                                | 39 (24–59)                   | 51 (31–63.5) | 50 (31.5–63.5)             | 56 (41.8–63.3) | 38 (23–58) |
| HIV positive                                        | 2954 (29.8)                  | 41 (41.4)  | 34 (45.3)                  | 76 (44.2)  | 2837 (29.4) |
| On ART (of HIV positive)                            | 2408 (81.5)                  | 34 (82.9)  | 28 (82.4)                  | 65 (85.5)  | 2309 (81.4) |
| History of TB                                       | 1196 (12.1)                  | 25 (25.3)  | 17 (22.7)                  | 110 (64.0) | 1061 (11.0) |
| Current smoker                                      | 726 (7.3)                    | 17 (17.2)  | 14 (18.7)                  | 30 (17.4)  | 679 (7.0)   |
| Cough currently                                     | 677 (6.8)                    | 14 (14.1)  | 12 (16.0)                  | 39 (22.7)  | 624 (6.5)   |
| Fever                                               | 295 (3.0)                    | 9 (9.1)    | 7 (9.3)                    | 13 (7.6)   | 273 (2.8)   |
| Weight loss in prior 6 months                       | 232 (2.3)                    | 10 (10.1)  | 8 (10.7)                   | 10 (5.8)   | 212 (2.2)   |
| Night sweat                                         | 326 (3.3)                    | 8 (8.1)    | 6 (8.0)                    | 12 (7.0)   | 306 (3.2)   |
| Any TB symptom                                      | 1056 (10.7)                  | 20 (20.2)  | 15 (20.0)                  | 45 (26.2)  | 991 (10.3)  |
| Any lung field abnormality according to radiologist | 2002 (20.2)                  | 80 (80.8)  | 64 (85.3)                  | 171 (99.4) | 1751 (18.2) |
| Chest x-ray diagnostic of TB according to radiologist| 202 (2.0)                    | 30 (30.3)  | 25 (33.3)                  | 172 (100)  | 0 (0)       |
| CAD4TBv5 scores*                                    | 28 (22–41)                   | 63 (44–77.5)| 66 (51.5–84)              | 87 (73–95) | 27 (22–40)  |
| CAD4TBv6 scores*                                    | 35 (16–46)                   | 61 (48.5–78)| 64 (52–78)                | 78 (68–87) | 34 (16–46)  |

Characteristics are listed among all enrolled participants who underwent chest radiography (n = 9914) and by TB diagnostic group: definite TB (microbiologically confirmed), definite TB, trace excluded (a more stringent group that excludes those whose only microbiological evidence of TB is an Xpert "trace" results), probable TB (radiologically diagnosed). Characteristics are shown as absolute frequencies (relative frequencies in %), or median* (25–75% interquartile range (IQR)) for age and CAD4TB scores.
majority (59.6%) of participants for sputum testing. Testing the sputum of participants with low CAD4TBv5 scores revealed that definite TB cases had a wide range of CXR abnormality (Figs. 2 and 3). Over a third of the definite TB cases (33/99, 35.3%) had a CAD4TB v5 score lower than 60, which has been shown to be more than 80% sensitive for case-finding in retrospective clinical settings. We considered whether the high HIV prevalence in this study population may have lowered CAD4TB scores in the definite TB group. Previous studies have shown that CXRs of HIV positive individuals with definite TB showed less TB-typical cavitation and more unspecific infiltrations. However, we did not find evidence of different CAD4TB scores by HIV status, which may be due to the high rate of antiretroviral therapy use with the resulting long-term viral suppression and immune reconstitution in our population. Another possible explanation for the wide range of CAD4TB scores among individuals with definite TB is that disease diagnosed through community-based screening represents an earlier “subclinical” stage of TB pathogenesis that is characterized by more subtle radiologic abnormalities on CXR. The existing CXR libraries that are available to train CAD algorithms use clinically diagnosed TB as their references and thus may not be optimized to detect subclinical TB. CAD4TB is a proprietary

Fig. 2 Radiographic spectrum of two participants with microbiologically confirmed active TB. Digital CXR images and the corresponding CAD4TBv5 heatmaps (blue colors mark normal lung fields and red marks TB-related abnormalities contributing to CAD4TB score). Participant 1 (a, b) was 62 years old, HIV-positive on ART, and had a CAD4TB v5 score of 95 which the radiologist assessed as abnormal and diagnostic of TB. Participant 2 (c, d) was 31 years old, HIV-negative, and had a CAD4TB v5 score of 39, which the radiologist assessed as normal. Both participants had positive liquid culture and XpertUltra (greater than trace) results, no TB symptoms, and no history of previous TB treatment.
algorithm and the demographic and clinical characteristics of the training data are unpublished. Therefore, it is unclear to what extent community-diagnosed asymptomatic TB has been used to train CAD4TB. It would be interesting to see if CAD4TB and other CAD-algorithms can be refined to detect early, radiologically subtle patterns of TB that is not yet clinically apparent. Increasing the transparency of algorithmic development could potentially speed up the refinement of CAD for this use.

A challenge to applying CAD for community-based screening is that it requires the selection of a triaging threshold that is optimized for the study aims, number of available microbiological tests, and underlying TB prevalence. An inappropriately high triaging threshold choice may fail to capture all TB cases leading to underestimation of prevalence. A threshold that is too low may cause high costs and labor for laboratory diagnostics of sputum. In many cases, it is necessary to conduct a pilot phase to optimize the triaging threshold for new settings. Ideally, this pilot should avoid the selection of an empirical triage threshold and should instead test the sputum of all pilot participants to capture the full spectrum of active TB disease and provide unbiased data to determine an optimal triage threshold. Our experience with CAD4TBv5 and its successor CAD4TBv6 indicates that threshold adjustment is required when applying a new CAD4TB version. Threshold choice needs to be balanced between maximal case finding and cost-effectiveness. Due to cost constraints, public health settings are likely to favor a threshold that performs equivalently to an expert radiologist. We recommend that research programs consider a lower threshold that allows additional identification of radiologically subtle TB cases.

The limitations of our study include that only a single radiologist performed independent CXR reading that might have biased our analysis. As recommended by the WHO, the radiologist was instructed to overcall abnormality, but he may have been overly sensitive to very subtle abnormalities influencing the selection of our triaging threshold during the pilot stage. Further limitations are that only single-spot sputum was the basis of microbiological data, which may have underestimated the number of definite TB cases. It is possible that we overestimated definite TB cases because of the inclusion of XpertUltra trace results. More research is necessary to determine whether individuals with XpertUltra "trace only" results represent early subclinical TB stages or if their results are false positives. We attempted to address the uncertainty about "trace only" results using a sensitivity analysis that excluded these cases (definite TB trace excluded) and did not find significantly different results. An additional limitation is that we did not collect sputum from participants who (1) were asymptomatic and had a CAD4TBv5 score below 25 \( n = 3772 \), (2) were unable to produce sputum in the camp \( n = 1112 \), and (3) could not be reached at home during a follow-up visit \( n = 54 \). The true TB status of those participants is unknown. The setting of our survey is a community with exceptionally high HIV prevalence, which may limit the generalizability of our findings to other active case-finding programs. A strength of our study is that the TB screening program was conducted as part of a multi-disease screening and bio-banking study within a demographical and health surveillance site. This means that the participants presented here have additional linked data describing clinical comorbidities, backed bio-specimens from the time of the survey, and are being actively followed through ongoing demographic and health surveillance activities.

During a multi-disease health screening in an HIV-endemic rural area, we prospectively evaluated the ability of CAD4TB to interpret digital CXRs and triage participants for microbiological sputum testing. Piloting indicated that a low threshold would be required to achieve our goal of maximum active TB detection. We found that 1.0% of our population had microbiologically confirmed TB and that these cases had a spectrum of radiological findings that ranged from highly abnormal to normal. Both CAD4TBv5 and CAD4TBv6 were able to achieve similar sensitivity to an expert radiologist in triaging CXRs for sputum collection, but only CAD4TBv6 also had a triaging threshold that achieved comparable specificity to the radiologist. Definite TB cases were largely asymptomatic (79.8%) and would have been missed in the absence of the digital CXR screening survey. With the caution that future applications may require setting-specific piloting to guide threshold selection, our data indicate that CAD4TB has the potential to replace human readers for CXR triaging in TB prevalence surveys.

**METHODS**

**Study design**

The multi-disease community-based screening program ‘Vukuzazi’ used mobile vans to provide free health assessments in the rural uMkhanyakude district of KwaZulu-Natal in South Africa. The data for this analysis were collected during the first year of the project (between 25 May 2018 and 24 May 2019). Study field workers visited households to explain and provide the study description and invite eligible residents to participate. Eligibility criteria included a minimum age of 15 years and ongoing residency in the

![Fig. 3 CAD4TB scores differ by TB but not HIV status. CAD4TB v5 (a) and v6 (b) distributions across TB diagnostic groups: definite TB (microbiologically proven \( n = 99 \)), definite TB, trace excluded (a more stringent group that excludes those whose only microbiological evidence of TB is an Xpert "trace" results, \( n = 75 \)), probable TB (radiologically diagnosed, \( n = 172 \)), and no evidence of TB (\( n = 9643 \)). Scores in each group were stratified by HIV status (definite TB HIV-positive: \( n = 41 \), HIV-negative: \( n = 57 \); definite TB, trace excluded HIV-positive: \( n = 34 \), HIV-negative: \( n = 40 \); probable TB HIV-positive: \( n = 76 \), HIV-negative: \( n = 96 \); no TB HIV-positive: \( n = 2383 \), HIV-negative: 6755). Horizontal lines mark the median. P-values from comparisons between HIV-positive vs. HIV-negative in each diagnostic group were for definite TB: 0.26 (v5), 0.26 (v6), definite TB, trace excluded: 0.70 (v5), 0.95 (v6), probable TB: 0.88 (v5), 0.06 (v6) no TB 2.9x10^-5 (v5), 0.70 (v6).](https://example.com/fig3.png)
Participants provided written informed consent to participate in the study. In the case of participant age under 18, consent was also obtained from the parents or guardians. At the camp, participants answered questions in their preferred language about smoking, TB symptoms and history, HIV history, and treatment, and the information was captured digitally. HIV status was assessed by a 4th-generation antibody/antigen test (Genscreen Ultra HIV Ag-Ab, Bio-Rad, Marnes-la-Coquette, France) on venous blood.

Posterior–anterior digital CXRs were obtained by a health worker using a mobile unit (Canon CXDI-NE) and the obtained digital CXRs were uploaded uncompressed in DICOM format into cloud storage. On a local workstation at the camp, the commercially available software CAD4TBv5 calculated scores off-line for each CXR, indicating lung abnormalities and the likelihood of active pulmonary tuberculosis. CAD4TBv5's methodology is based on initial lung field segmentation and subsequent analysis of the lung shape, symmetry, and costophrenic angles, resulting in an abnormality score between 0 and 100 (increasing with abnormality). The output score reflects the probability of active TB visible on the CXR. Following WHO guidelines for TB prevalence surveys, participants were referred for sputum examination if they reported any cardinal TB symptom (fever, weight loss, cough, or night sweats) or if they had an abnormal CXR (indicated by a CAD4TBv5 score equals or higher than the triaging threshold in the camp). Sputum specimens were analyzed for Mtb using Xpert Ultra MTB/RIF (Cepheid, Sunnyvale, CA, USA) and liquid...
Table 2. Performance of CAD4TBv5 and v6 to identify confirmed TB at the radiologist’s sensitivity.

| Test                        | Sensitivity % (CI) | Specificity % (CI) | PPV % (CI) | NPV % (CI) | % of participants required to test (absolute n) NNT | Cases missed (%) |
|-----------------------------|--------------------|--------------------|------------|------------|---------------------------------------------------|-----------------|
| Radiologist                 | 88.8 (71.7–98.0)   | 66.9 (55.6–88.2)   | 4.7 (3.8–5.8) | 99.4 (99.1–99.7) | 20.2 (2002) | 25 (19.2) |
| CAD4TBv5: 39                | 82.8 (73.9–89.7)   | 55.4 (54.0–89.7)   | 3.6 (2.9–4.5) | 99.4 (99.1–99.7) | 28.4 (2820) | 34 (17.2) |
| CAD4TBv5: 40                | 78.8 (70.5–87.7)   | 57.4 (56.0–86.8)   | 3.7 (2.9–4.5) | 99.4 (98.9–99.6) | 27.0 (2707) | 29 (17.2) |
| CAD4TBv5: 47                | 73.8 (65.2–84.7)   | 62.6 (61.2–64)     | 4.3 (3.4–5.3) | 99.4 (99.1–99.7) | 23.7 (2348) | 26 (23.2) |
| CAD4TBv5: 48                | 68.0 (56.9–79.9)   | 68.0 (66.7–69.3)   | 4.6 (3.7–5.8) | 99.4 (99.1–99.7) | 20.1 (1997) | 26 (23.2) |

Definite TB was defined as microbiological evidence, either by positive XpertUltra or culture. Presented are the radiologist’s sensitivity to triage definite TB by classifying any lung field abnormality in comparison to CAD4TBv5 scores that closely matched the radiologist’s sensitivity. Performance is given as sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) with 95% confidence intervals (CI).

Obtaining a triaging threshold

Triaging with CAD4TB requires selecting a CAD4TB score as an optimal triaging threshold. The aim of our survey was to maximize TB case-finding and to capture the full spectrum of active TB within the community. We conducted a pilot phase with 1090 participants who underwent chest radiography with an initially chosen CAD4TBv5 threshold of 60, seeking to adjust this threshold to match the radiologist’s ability to identify abnormal lung fields. When planning the study, existing literature at that time showed CAD4TB thresholds around 60–65 to be more than 80% sensitive for active TB. Based on those, we selected a CAD4TBv5 threshold of 60 to triage participants for sputum examination during the pilot phase, seeking to adjust this threshold after evaluating its performance. If during the pilot phase the expert radiologist indicated abnormal lung fields despite a CAD4TBv5 score below the threshold, a follow-up team contacted participants for sputum collection at home. After the pilot phase, we compared CAD4TBv5 scores to the radiologist’s assessment of abnormal lung fields and obtained threshold 25 that had a sensitivity of 85% to identify abnormal lung fields. CAD4TB threshold 25 was used to triage participants for the remainder of the study.

Data analysis

CAD4TBv6, an updated version of the image interpretation software that uses deep neural networks, became available after data collection. CAD4TBv6 scores were calculated and analyzed retrospectively. We assessed the performance of CAD4TBv5 and v6 to identify any lung field abnormality like the radiologist. We compared the categorization of any lung field abnormality by the radiologist and CAD4TBv5 and v6 to diagnostic definitions of TB (definite TB, definite TB trace excluded, and probable TB). The results are reported following Standards for Reporting of Diagnostic Accuracy (STARD). Performance was assessed by sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), area under the receiver-operating curve (AUC), and area under the precision-recall curve (PRAUC). Estimations of 95% confidence intervals (CI) are given. AUCs between CAD4TBv5 and v6 and HIV-positive and -negative participants were compared using the DeLong method. For each CAD4TB threshold, we calculated the percentage (relative to all participants, n = 9914) and an absolute number of participants who had an equal or higher score. Similar to Qin et al., we calculated the number of needed sputum tests (NNT) which is required to find one person with definite TB and definite TB trace excluded and the number of missed TB cases for the radiologist and each CAD4TB score from 0–100. Missed TB cases were defined as the number of TB cases below each threshold. Missed TB cases were obtained for definite TB, definite TB trace excluded, and probable TB definitions and stratified by symptom status. We compared CAD4TB scores between diagnostic groups of definite and probable TB, stratified by HIV status, and assessed significant differences using two-sided Mann–Whitney–Wilcoxon tests.

Data analysis was performed with R (version 4.0.3) using the packages ‘epiR’, ‘pROC’, and ‘precrec’.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

DATA AVAILABILITY

The Vukuzazi screening protocol as well as the dataset analyzed during the current study may be accessed via the AHRI Data Repository at https://data.ahri.org/index.php/catalog/990 upon approval of proposed analyses by the Vukuzazi Scientific Steering Committee and completion of a data access agreement.
CODE AVAILABILITY

CAD4TB is a proprietary software and the code is not publicly available. For questions about CAD4TB, please refer to Delft Imaging (https://www.delft.care/cad4tb/).

Received: 20 September 2020; Accepted: 21 May 2021; Published online: 02 July 2021

REFERENCES

1. World Health Organization (WHO). WHO End TB Strategy. https://www.who.int/tb_strategy/en/ (2017).
2. Pai, M., & Dewan, P. Testing and treating the missing millions with tuberculosis. PLoS Med. 12, 10–12 (2015).
3. Mahase, E. Millions of people are still missing out on TB treatment, says WHO. BMJ 367, i6097 (2019).
4. Cortett, E. L. et al. Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial. Lancet 376, 1244–1253 (2010).
5. Creswell, J. et al. Programmatic approaches to screening for active tuberculosis. Int. J. Tuberc. Lung Dis. 17, 1248–1256 (2013).
6. Creswell, J. et al. A multi-site evaluation of innovative approaches to increase tuberculosis case notification: summary results. PLoS One 9, e94465 (2014).
7. Hanna, B. A. et al. Multi-center evaluation of the BACTEC MGT 960 system for recovery of mycobacteria. J. Clin. Microbiol. 37, 748–752 (1999).
8. Boehme, C. C. et al. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363, 1005–1015 (2010).
9. van’t Hoog, A. H. et al. Screening strategies for tuberculosis prevalence surveys: the value of chest radiography and symptoms. PLoS One 7, 1–9 (2012).
10. World Health Organization. Chest radiography in tuberculosis detection: summary of current WHO recommendations and guidance on programmatic approaches. https://www.who.int/tb/publications/chest-radiography/en/ (2016).
11. World Health Organization. WHO announces forthcoming updates on the systematic screening for tuberculosis. https://www.who.int/news/item/07-12-2020-who-announces-forthcoming-updates-on-the-systematic-screening-for-tuberculosis (2020).
12. Zaidi, S. M. A. et al. Evaluation of the diagnostic accuracy of computer-aided detection of tuberculosis on chest radiographs among private sector patients in Pakistan. Sci. Rep. 8, 1–9 (2018).
13. Murphy, K., et al. Computer aided detection of tuberculosis on chest radiographs: an evaluation of the CAD4TB v6 system. Sci. Rep. 26,5499 (2019).
14. van Ginneken, B., Schaefer-Prokop, C. M. & Prokop, M. Computer-aided diagnosis: how to move from the laboratory to the clinic. Radiology 261, 719–732 (2011).
15. Muyoyeta, M. et al. The sensitivity and specificity of using a computer aided diagnosis program for automatically scoring chest X-rays of presumptive TB patients compared with Xpert MTB/RIF in Lusaka Zambia. PLoS One 9, 16–18 (2014).
16. Breuninger, M., et al. Diagnostic accuracy of computer-aided detection of pulmonary tuberculosis in chest radiographs: a validation study sub from Sabahan Africa. PLoS One https://doi.org/10.1371/journal.pone.016381 (2014).
17. Philippsen, R., Ginneken, B. Van & Melendez, J. Computer Aided Detection of Tuberculosis CAD4TB. https://www.delft.care/cad4tb/ (2018).
18. Qin, Z. Z., et al. Can artificial intelligence (AI) be used to accurately detect tuberculosis (TB) from chest X-ray? A multiplatform evaluation of five AI products used for TB screening in a high TB-burden setting. Preprint at https://arxiv.org/abs/2005.05509 (2020).
19. Rahman, M. T., et al. An evaluation of automated chest radiography reading software for tuberculosis screening among public- and private-sector patients. Eur. Respir. J. https://doi.org/10.1183/13993003.02519-2016 (2017).
20. Nathavitharana, R. R. et al. Guidance for studies evaluating the accuracy of tuberculosis triage tests. J. Infect. Dis. 220, S116–S125 (2019).
21. Kisembira, H. N. et al. Chest radiographic findings of pulmonary tuberculosis in severely immunocompromised patients with the human immunodeficiency virus. Br. J. Radiol. 85, 130–139 (2012).
22. Kistan, J. et al. Pulmonary TB: Varying radiological presentations in individuals with HIV in Soweto, South Africa. Trans. R. Soc. Trop. Med. Hyg. 111, 132–136 (2017).
23. Koescemadina, R. C. et al. Computer-assisted chest radiography reading for tuberculosis screening in people living with diabetes mellitus. Int. J. Tuberc. Lung Dis. 22, 1088–1094 (2018).
24. Melendez, J. et al. Automatic versus human reading of chest X-rays in the zambia national tuberculosis prevalence survey. Int. J. Tuberc. Lung Dis. 21, 880–886 (2017).
25. Wong, E. B. et al. Convergence of infectious and non-communicable disease epidemics in rural South Africa: a cross-sectional, population-based multimorbidity study. Lancet Glob Heal. 9, e967–76 (2021).
26. World Health Organisation. Tuberculosis Prevalence Surveys: A Handbook. (WHO, 2011).
27. Chakravorty, S. et al. The new Xpert MTB/RIF ultra: Improved detection of Mycobacterium tuberculosis and resistance to Rifampin in an assay suitable for point-of-care testing. MBio 8, 1–12 (2017).
28. Dorman, S. E. et al. Xpert MTB/RIF Ultra for detection of mycobacterium tuberculosis and rifampin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect. Dis. 18, 76–84 (2018).
29. Kendall, E. A. et al. The spectrum of tuberculosis disease in an urban Ugandan community and its health facilities. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa1824 (2020).
30. World Health Organization. Chest radiography in tuberculosis detection: a multi-site evaluation of the diagnostic accuracy of three deep learning systems. Sci. Rep. https://doi.org/10.1038/s41598-019-51503-3 (2019).
31. Tanser, F., Kim, H. Y., Vandormael, A., Iwujwi, C. & Bärmighausen, T. Opportunities and challenges in HIV treatment as prevention research: results from the ANRS 12249 cluster-randomized trial and associated population cohort. Curr. HIV/AIDS Rep. 17, 97–108 (2020).
32. Jaeger, S. et al. Two public chest X-ray datasets for computer-aided screening of pulmonary diseases. Quant. Imaging Med. Surg. 4, 475–477 (2014).
33. Qin, Z. Z. et al. A new resource on artificial intelligence powered computer automated detection software products for tuberculosis programmes and implementers. Tuberculosis 127, 102049 (2021).
34. Ngwenya, N., Luthuli, M., Gunda, R., Gumede, N. A. & Adeagbo, O. Participant understanding of informed consent in a multidisease community-based health screening and biobank platform in rural South Africa Nandoth. Int. Health 12, 560–566 (2020).
35. Pillay, D., Koole, O. & Wong, E. B. Performance of computer-aided chest radiography for detection of TB in a community-based multimorbidity cohort in rural KwaZulu-Natal, Africa Health Res. https://doi.org/10.23664/1444YUKUZAI-CHESTXRAYPAPERS (2020).
36. Delft. CAD4TB white paper. https://www.delft.care/cad4tb/ (2016).
37. Hogeweg, L. et al. Automatic detection of tuberculosis in chest radiographs using a combination of textural, focal, and shape abnormality analysis. IEEE Trans. Imaging Med. 34, 2429–2442 (2015).
38. Bossuyt, P. M. et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ 351, 1–9 (2015).

ACKNOWLEDGEMENTS

‘Vukuzazi’ was the collective effort of a large team (see Supplementary Information). We thank the community of the ukhanyakude district in KwaZulu-Natal for participating in this study. We acknowledge the members of the AHRI Community Advisory Board and the local and provincial Department of Health in their support of this project. We thank Delft for providing CAD4TBv6 scores free of charge. We dedicate this paper to the memories of Anand Rammanan and Sibahle Gumbi who made major contributions to the Vukuzazi Project. The community screening program ‘Vukuzazi’ is funded by the Africa Health Research Institute, the Wellcome Trust (201433/2/16/Z), and the Bill and Melinda Gates Foundation (OPP1175182). Additional funders include NIAID (R08AI18538) and FIC (TW101687), National Institutes of Health, and CDC-TB Center (Contract # 7S93090300070). The funders had no role in study design, data analysis, and interpretation, or writing of the report. The mobile CXR unit including the real-time use of the CAD4TBv6 software was leased from Aurum Innova in partnership with Delft. The retrospective calculation of CAD4TBv6 scores was provided by Delft free of charge. Delft provided no funding and had no other role in this study. TN is supported through the South Africa Research Chairs Initiative (grant # 64809) and the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative (grant # DEL-15-006). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS’s) Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and
Author Contributions

J.F. performed data analysis with figures and tables and writing of the report. S.O. and K.B. contributed to data analysis. D.G. contributed to data management. R.G., A.S., D.P., O.K., W.H., and M.J.S. contributed to study design. T.S., S.M., and T.N. contributed to the laboratory study setup and provision of test results. A.D.G. contributed to study design and analysis conceptualization. S.K. and C.L. contributed to data analysis and supervision. E.B.W. study design, analysis conceptualization, revision, and supervision. All authors contributed to the revision of the manuscript and approved the final version.

Ethics Declarations

Ethics approval was obtained from the University of KwaZulu-Natal Biomedical Research Ethics Committee (BES60/17), the London School of Hygiene & Tropical Medicine Ethics Committee (14722), and the Partners Institutional Review Board (2018P001802).

Competing Interests

We declare no competing financial or non-financial interests. CAD4TBv5 scores were purchased from Delft but CAD4TBv6 scores were provided free of charge. Delft did not contribute any funding and was not involved in the analysis and writing of the report.

The Vukuzazi Team

Alison D. Grant,1,4,6,10 Anand Ramnanan,2 Anele Mkhwanazi2, Antony Rapulana,2 Anupa Singh2, Ashetha Govender2, Ashmika Surujdeen,1, Ayanda Zungu2, Boitsholo Mfolo14, Bongani Magwaza2, Bongumenzzi Ndlouv1,2, Clive Mavimbel2,2, Costa Criticos2, Day Mumnatis2, Deenan Pillay15, Dickman Gareta,2 Dilip Kalyan,2 Doctar Mlambo2, Emily B. Wong1,11,12,13,20, Fezeko Mfeka2,2, Freddy Mabetela2, Gregory Ording-Jesper2, Hannah Keal2,2, Hlengiwe Dlamini2, Hlengiwe Khathi2,2, Hlobisile Chonco2, Hlobisile Gumede2, Hloniphile Khumalo2, Hloniphile Ngubane2, Hollis Shen2,2, Hosea Kambonde15, Innocentia Mpofana2,2, Jabu Kwindwa14, Jaco Dreyer2,2, Jade Cousins2,2, Jaikrishna Kalideen16, Janet Seeley6, Kandaseelan Chetty2, Kayleen Brien2,2, Kennedy Nyamande17, Kgaugelo Moropane14,18, Khabonina Malomane14, Khadija Khan2,2, Khanyisani Buthelezi2, Kimeshree Perumal2, Kobus Herbst2, Lindani Mthembu2, Logan Pillay2, Mandisi Dlamini2, Mandlakayise Zikhali2, Mark J. Siedner,1,10,11,12, Mbal Xibuyisa2, Mbuti Mofokeng2, Melusi Sibiya2,2, Mlungisi Dube2,2, Mosa Suleman17, Mpumelo Steto2,2, Mzamo Buthelezi2,2, NagaPavi Dayachay2, Nceba Gqalen12-18, Ngcebo Mhlongo2,2, Nokukhanya Ntshakala1,2, Nomathamsanqa Majozi2, Nombuyiselo Zondi2,3, Nonfuno Luthuli2,3, Nomfuno Ngema2,4, Nompilo Buthelezi2, Nompilo Mfeka2,2, Ntombi Phathabo2,2, Nonfuno Luthuli2, Nomfuno Ngena2, Nompilo Mfeka2,2, NonluXonis Mabaso2,2, Nchumusha Shibanda2,2, NonluXonis Zhitha2,2, NonluXonis Mfikayi2,2, NonluXonis Mzimela2,2, Nozipho Mbonambi2,2, Ntombiyenhlanhla Mkhwanazi2, Ntombiyenhlanhla Mntombela2, Olivier Koole1,1,6,10, Pamela Ramkalawon2, Pfarelo Tshivhase17, Phakamani Mkhwanazi2, Philippa Mathews2, Phumelele Mthethwa2, Phumlale Ngcobo2,2, Ramesh Jackpersad19, Raymond Zondo2,2, Resign Gunda1,4,5, Rochelle Singh2,2, Rose Myeni2, Sanah Bucibo2, Sphiwe Clement Mthembu2, Sphiwe Mntombela2, Sphiwe Ntuli2,2, Stephen Olivier2,2, Talente Ntimbane2,2, Thabile Zondi2,2, Thandeka Khosa2,2, Thengokwakhe Nkosi2,2, Theresa Smit2, Thokozani Bhengu2,2, Thokozani Simelane2,2, Thobi Ndongu1,5,7,8,9, Tshwaraganang Modise2, Tumi Madolo2,2, Velile Velemen2,2, Welcome Petros Mthembu2, and Willem Hanekom1,5,15, Xolani Mkhize2,2, Zamashandu Mbatha2,2, Zinhile Buthelezi2,2, Zinhile Mthembu2, and Zizzle Sithosana2.

Additional Information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41746-021-00471-y.

Correspondence and requests for materials should be addressed to E.B.W.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021

npj Digital Medicine (2021) 106

Published in partnership with Seoul National University Bundang Hospital